| P50 | author | Ching-Lung Lai | Q56885069 |
| P2093 | author name string | Man-Fung Yuen | |
| P2860 | cites work | The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study | Q81156601 |
| | Prevalence of HBV and HCV dual infection in patients on haemodialysis | Q81802980 |
| | Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers | Q83218996 |
| | Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants | Q84401410 |
| | Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells | Q27486067 |
| | Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients | Q28375088 |
| | EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 |
| | Chronic hepatitis B: update 2009 | Q29617409 |
| | Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. | Q33939443 |
| | Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation | Q34200824 |
| | Safety of tenofovir during pregnancy for the mother and fetus: a systematic review | Q34371989 |
| | The HBV drug entecavir - effects on HIV-1 replication and resistance | Q34639926 |
| | Hepatitis B virus DNA contains a glucocorticoid-responsive element | Q35594395 |
| | A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. | Q35595459 |
| | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 |
| | Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation | Q35832747 |
| | The management of HIV and hepatitis B coinfection | Q36696371 |
| | Prophylaxis and treatment of hepatitis B in immunocompromised patients | Q36768889 |
| | Understanding the pathogenesis and management of hepatitis B/HIV and hepatitis B/hepatitis C virus coinfection | Q36991488 |
| | Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy | Q37124256 |
| | The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients | Q37293650 |
| | Treatment of HBV/HCV coinfection | Q37694558 |
| | Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action | Q37765836 |
| | Management of HIV and hepatitis virus coinfection | Q37772508 |
| | HIV and viral hepatitis coinfections: advances and challenges | Q38002790 |
| | Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. | Q38056581 |
| | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs | Q38155954 |
| | Recurrent hepatitis B in liver allografts: a distinctive form of rapidly developing cirrhosis | Q38485471 |
| | Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy | Q39174492 |
| | The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains | Q39876916 |
| | Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein | Q40688252 |
| | Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization | Q42227338 |
| | Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine | Q42242051 |
| | Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin | Q42540557 |
| | A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection | Q42606604 |
| | An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals | Q42690485 |
| | Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus | Q42923518 |
| | Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids | Q42970629 |
| | Hepatitis C genotypes in patients with dual hepatitis B and C virus infection | Q42979015 |
| | Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses | Q42983894 |
| | The significance of antibody to hepatitis C virus in patients with chronic hepatitis B. | Q42984320 |
| | Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers | Q42986433 |
| | Hepatitis B and C Viruses and Their Interaction in the Origin of Hepatocellular Carcinoma | Q42986543 |
| | HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. | Q42997128 |
| | Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection | Q43032316 |
| | Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study | Q43035912 |
| | Prevalence and significance of hepatitis C viremia in chronic active hepatitis B. | Q43042528 |
| | Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus | Q43433204 |
| | Hepatitis B antigen in infants born to mothers with chronic hepatitis B antigenemia in Taiwan | Q43699715 |
| | FDA: Increased HBV reactivation risk with ofatumumab or rituximab | Q43837340 |
| | Determination of serum hepatitis B virus DNA in chronic HBsAg carriers: clinical significance and correlation with serological markers. | Q43944072 |
| | Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication | Q44080063 |
| | Two fatal cases of hepatitis B virus carriers after corticosteroid therapy for bronchial asthma | Q44170003 |
| | Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. | Q44222724 |
| | Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. | Q44226653 |
| | Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. | Q44231599 |
| | Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients | Q44286170 |
| | The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. | Q44425133 |
| | Hepatitis B surface antigen carrier status and its correlation to gestational hypertension | Q44476615 |
| | Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge | Q44485961 |
| | Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study | Q44671788 |
| | Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up | Q44712043 |
| | HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). | Q44933768 |
| | Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C. | Q44978856 |
| | Vertical Transmission of Hepatitis B Antigen in Taiwan | Q45146867 |
| | Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture | Q45227764 |
| | Natural history of hepatitis B and C in renal allograft recipients | Q45268885 |
| | Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series | Q45357942 |
| | Perinatal transmission of hepatitis B virus: an Australian experience | Q45384871 |
| | Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. | Q45387049 |
| | Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. | Q45388033 |
| | Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy | Q45394694 |
| | Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. | Q45729501 |
| | Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. | Q45750465 |
| | Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes | Q45771892 |
| | The threat of hepatitis B virus recurrence: a sword of Damocles to the liver transplant recipient | Q45776430 |
| | Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study | Q45783032 |
| | Non-A, non-B hepatitis in chimpanzees: interference with acute hepatitis A virus and chronic hepatitis B virus infections | Q45795849 |
| | Interference between non-A, non-B and hepatitis B virus infection in chimpanzees | Q45795851 |
| | Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families | Q45853546 |
| | The outcomes of pregnancy in patients with cirrhosis: a population-based study | Q46136397 |
| | Chronic hepatitis B--new goals, new treatment. | Q46217480 |
| | New paradigms for the treatment of chronic hepatitis B. | Q46476325 |
| | Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. | Q46794204 |
| | Exacerbation of chronic hepatitis B infection after delivery | Q46844424 |
| | Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany | Q51745491 |
| | Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases. | Q51761171 |
| | Rituximab treatment results in impaired secondary humoral immune responsiveness. | Q52010866 |
| | Coinfection with hepatitis B and C or B, C and delta viruses results in severe chronic liver disease and responds poorly to interferon-alpha treatment. | Q54019036 |
| | Treatment of fibrosing cholestatic hepatitis with lamivudine | Q58236274 |
| | Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. | Q64897452 |
| | Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders | Q66841235 |
| | Symptomatic reactivation of hepatitis B in pregnancy | Q68291418 |
| | Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study | Q72577857 |
| | Liver transplantation in European patients with the hepatitis B surface antigen | Q72623987 |
| | Coinfections by HIV, hepatitis B and hepatitis C in imprisoned injecting drug users | Q73167353 |
| | Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab | Q73460170 |
| | Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV | Q80239756 |
| | Safety and tolerability of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals | Q80590892 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic hepatitis B | Q55779876 |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | Management of chronic hepatitis B in patients from special populations | |
| P478 | volume | 5 | |